CARIS LIFE SCIEN. A O.N.

Caris Life Sciences reported Q1 2026 revenue up 79% to $216.2 million, with molecular profiling revenue rising 85%, gross margin expanding to 65%, and positive adjusted EBITDA and free cash flow. Growth was driven by higher average selling prices and recovering case volumes after a temporary sales-force disruption, while management signaled reimbursement concerns may be less severe than feared. The company is transitioning from core profiling into a multi-product platform with offerings like Caris Detect, ChromaSeq and MI Clarity; investors will watch Q2 case conversion, ASP stability, and early adoption of new tests to validate sustained expansion. » More on finance.yahoo.com

Caris Life Sciences reported revenue of $216m for Q1 2026 (+79% y/y), driven by an increase in molecular profiling services to $211m (+85%), and a gross margin of 65%. Adjusted EBITDA was positive at $26m and free cash flow was $23.5m; EPS was $0.00, beating the $-0.12 expectation. Despite the results, the stock fell 15.58% after the earnings call and extended losses in premarket trading, while the company introduced new products (Caris ChromoSeq, Caris MI Clarity), refinanced debt through 2031 and guided revenue of $240.14m for Q3 2026. » More on de.investing.com

Caris Life Sciences reported a 79% revenue increase to $216.2 million in Q1 2026 and breakeven earnings per share versus an expected shortfall of $0.12. The GAAP net loss narrowed to $0.5 million, adjusted EBITDA was $26.2 million, and free cash flow was positive at $22.5 million. Growth was driven by a 61% rise in average selling price and volume gains in tissue and blood tests; gross margin increased to 65%. Caris reaffirmed its full-year revenue guidance of $1.00–1.02 billion and emphasized continued investments in sales and the pipeline. » More on de.investing.com